Search Results

Highlights: • The Foundry Arrives : R&D meets biotech with real-world acceleration, strategic consulting GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

work at Alkermes didn’t just improve drug screening outcomes, it redefined what great leadership in biotech

GPCR Premium Membership Gives You an Edge Premium gives GPCR scientists and biotech teams a single, trusted Researchers, pharmacologists, biotech teams, and decision-makers who rely on accurate, efficient, interpretation-first

Explore this week’s research, tools, and biotech insights in one place.

Biotech teams, CRO alliances, and academic consortia face the same challenge: how to align incentives This ecosystem design blueprint applies to biotech teams and academic consortia alike.

Kenakin Trusted insights from biotech, pharma, and academia 🎬 Plus New: Lesson Trailers   Curious about GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

His hybrid path is a model of possibility for professionals in the biotech industry who still dream of

In this podcast, he lays out the mindset that helped shape products used across biotech and academia—and teaming, testing, and failing smarter. 🚀 Why This Matters: Whether you’re launching a tool, starting a biotech

GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need tools, translational strategy, classified updates, and curated jobs—trusted by scientists, teams, and biotech

Did you know that each month we collect the most recent #GPCR publications and the newest Biotech/Pharma

🔹 Spot the opportunity → Why Catalio is betting big when others pull back Amid biotech slowdowns

Explore this week’s research, tools, and biotech insights in one place.

(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company

School of Medicine to Receive $3-Million Award from ARPA-H’s Sprint for Women’s Health Nxera Pharma Wins Biotech Year and Financing Deal of the Year at the Citeline Japan Awards 2024 GPCR therapies: Eight promising biotechs

Industry News Domain Therapeutics was one of the 4 Biotech Trophy nominees at 2023 HealthTech awards. The delisting dilemma: Why do so many biotechs face being kicked off the Nasdaq?. (April 20 - 21, 2023) Swiss Biotech Day (April 24 - 25, 2023) SLAS Europe 2023 Conference and Exhibition

productive lab—it accelerated outcomes and laid the cultural foundation for the next generation of biotech insights from major conferences, emerging research, and expert commentary Whether you’re a pharmacologist, biotech

Explore this week’s research, tools, and biotech insights in one place.

Explore this week’s research, tools, and biotech insights in one place. The insights are ready.

The Boston biotech revealed Wednesday afternoon that it would downsize its research to focus on its lead

insights from major conferences, emerging research, and expert commentary Whether you’re a pharmacologist, biotech GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

About Celtarys Research Celtarys Research is a biotech company based in Spain that specializes in the

pathway of opioid drugs into cellular structures Inversago Pharma will present at BBHIC 2023 Orion Biotechnology attended the Swiss Biotech Day Addex Therapeutics attended the Swiss Biotech Day Sosei Heptares presented

January 2022 "G-protein-coupled receptors’ star has been on the rise in biotech in recent years as researchers

fruitful research space has led to more than 700 approved drugs over previous decades—but the two-year-old biotech

Plus: must-read chemokine and PTH1R papers, and new momentum across biotech—from Superluminal to Neurocrine

That money has gone to some 60 biotechs, much of it as early funding."

and models of physiological ligand complexes Reviews, GPCRs, and more Sensing host and environmental cues

(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced

Joanne Waldstreicher to its Board of Directors GPCR Therapeutics launches multiple myeloma trial Salipro Biotech organized by LINK-J Jounce takes the cash under amended deal with Gilead on anti-CCR8 antibody InterAx Biotech

Our partner, Domain Therapeutics, will attend the SACHS 23rd annual biotech event in Europe. Dr. Therapeutics CEO Pascal Neuville to Discuss Game-Changing GPCR-Targeting Immunotherapies at Sachs Associates' Biotech